CCM
JNCE

CAAS Capital Management’s Jounce Therapeutics, Inc. Common Stock JNCE Stock Holding History

CAAS Capital Management’s Portfolio JNCE Stock Details JNCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-1,052,437
Closed -$10.8M – 1390
2021
Q1 		$10.8M Buy
+1,052,437
New +$11.5M 0.12% 202

Other funds holding JNCE

TGI
TRV GP II Boston, Massachusetts $1.34M AUM 67.55% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
TGI
TRV GP III Boston, Massachusetts $6.14M AUM 45.44% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

CAAS Capital Management's JNCE Position: Q2 2021 in Review

CAAS Capital Management sold out of Jounce Therapeutics, Inc. Common Stock (JNCE) in Q2 2021, closing a stake of 1,052,437 shares — an estimated $10.8M sold.

CAAS Capital Management first reported a position in JNCE in Q1 2021 and held it in 1 quarter. The position peaked at $10.8M in Q1 2021. 130 funds tracked by Wall St. Rank hold JNCE as of Q2 2021.

  • CAAS Capital Management reported no remaining Jounce Therapeutics, Inc. Common Stock position as of Q2 2021 after selling out during the quarter.
  • CAAS Capital Management sold 1,052,437 Jounce Therapeutics, Inc. Common Stock shares in Q2 2021, an estimated $10.8M.
  • CAAS Capital Management first reported a position in Jounce Therapeutics, Inc. Common Stock in Q1 2021 and held it in 1 quarter.
  • CAAS Capital Management's Jounce Therapeutics, Inc. Common Stock position peaked at $10.8M in Q1 2021.
  • 130 funds tracked by Wall St. Rank held Jounce Therapeutics, Inc. Common Stock as of Q2 2021.

Based on CAAS Capital Management's 13F filing for Q2 2021, filed 16 Aug 2021.